Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. OBJECTIVE: To determine whether adding bevacizumab to erlotini...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Oncol
Main Authors: Stinchcombe, Thomas E., Jänne, Pasi A., Wang, Xiaofei, Bertino, Erin M., Weiss, Jared, Bazhenova, Lyudmila, Gu, Lin, Lau, Christie, Paweletz, Cloud, Jaslowski, Anthony, Gerstner, Gregory J., Baggstrom, Maria Q., Graziano, Stephen, Bearden, James, Vokes, Everett E.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2019
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6692685/
https://ncbi.nlm.nih.gov/pubmed/31393548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1847
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker